Compare Fidelity National Information Servcs Inc (FIS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Tango Therapeutics Inc. — how do they compare? Fidelity National Information Servcs Inc trades at $35.84 (market cap $18.15B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Fidelity National Information Servcs Inc is far larger — about 4.8× Tango Therapeutics Inc.'s market cap, and Fidelity National Information Servcs Inc pays a 5% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 89 Days and Tango Therapeutics Inc. for 0 Days on average.
| FIS | TNGX | |
|---|---|---|
Market Cap | $18.15B | $3.75B |
Volume | 8,219,694 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $67.94 | $32.90 |
52-Week Low | $32.44 | $7.50 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $38.66B | $2.77B |
Dividend Yield | 5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $35.47, up 3.53% with strong earnings beats in recent quarters. The stock shows bearish technical signals despite positive analyst sentiment with 57% buy ratings and a $45.50 consensus target. Fundamentals improved significantly with net income turning positive at $382 million in 2025 after prior losses, while revenue growth is projected to reach $12.2 billion in 2026. Recent business wins include core banking platform adoptions and embedded finance innovations.
FIS presents a compelling value opportunity with low P/E of 5.4 and strong profitability metrics, though technical indicators suggest near-term caution. Key risks include debt management challenges and competitive pressures in financial technology. The 27% upside to analyst targets and ongoing business momentum support a constructive outlook for patient investors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
